ClinicalTrials.gg
CompletedNCT05571943Updated Aug 9, 2024

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

A Phase 3 interventional study of Difamilast in Atopic Dermatitis, sponsored by Acrotech Biopharma Inc.. Completed at 63 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
542
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
Largest of 16
542 · median 177
Started
2022
with 2 others
Phase 3
10 of 16
2 open now
Registered
11th of 16
by date
Lead sponsor
2 of 16
Acrotech Biopharma Inc.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one has the largest enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD. The study will also evaluate the long-term efficacy of difamilast ointment 1%, including durability of response.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Important Inclusion Criteria:

  1. Subjects who are male or female ≥2 years of age at Screening (Visit 1).
  2. Subjects who have a diagnosis of AD based on the American Academy of Dermatology AD diagnostic criteria
  3. Subjects who have had a diagnosis of AD for at least 3 months prior to Screening .
  4. Subjects who have an IGA of mild or moderate AD Severity and treatable body surface area (BSA) ≥3%at Baseline if not previously enrolled in study MEDI-MM36-301 OR b. IGA ≤ 3, with no minimum BSA and completed through Week 4/EOT Visit 6 of the study MEDI-MM36-301.
  5. Subject is willing and able to comply with all study-related procedures, including, but not limited to, application of the study drug, and visit requirements.

Important Exclusion Criteria:

  1. Subjects who have an AD flare (defined as rapid intensification of AD) within 28 days prior to Screening or Baseline (except for those previously enrolled in Study MEDI-MM36-301) or history of consistent requirement for high-potency topical to manage AD signs and symptoms.
  2. Subjects who have an active or acute skin infection (eg, herpes simplex, herpes zoster, or chicken pox), and/or clinically infected AD
  3. Subjects with significant systemic or localized infection
  4. Subjects with minimal/mild depression and suicidal ideation
  5. Subjects using restricted medications, biologics and alternative therapies, or using drug

    -

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
542 participants (actual)

Study arms

  • Experimental
    Difamilast Ointment 1%

    A thin layer of Difamilast applied to affected areas twice daily (morning and evening, approximately 12 hours apart)

    Drug: Difamilast

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and their relationship to study drug

    Time frame: 52 week study period

  2. Proportion of subjects who discontinue due to an AE over the study period

    Time frame: 52-week study period

07

Study locations

63 sites
  • Qualmedica Research, LLC
    Birmingham, Alabama 35205, United States
  • AllerVie Health
    Birmingham, Alabama 35244, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • NEA Baptist Clinic-Dermatology
    Jonesboro, Arkansas 72405, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Southern CA Dermatology Skin and Laser
    Laguna Niguel, California 92677, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Clinical Trials Research Institute
    Thousand Oaks, California 91320, United States
  • Clarity Dermatology, LLC
    Castle Rock, Colorado 80109, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • TrueBlue Clinical Research
    Brandon, Florida 33511, United States
  • Annexus Dermatology & Aethestics
    DeLand, Florida 32720, United States
  • Accel Research - Edgewater Clinical Research Unit
    Edgewater, Florida 32132, United States
  • Skin Care Research
    Hollywood, Florida 33021, United States
  • Kirsch Dermatology
    Naples, Florida 34102, United States
  • Tory Sullivan, MD PA
    North Miami Beach, Florida 33162, United States
  • Pure Skin Dermatology & Aesthetics
    Orlando, Florida 32819, United States
  • Nona Pediatrics
    Orlando, Florida 32829, United States
  • Accel Research - Ormond Clinical Research Unit
    Ormond Beach, Florida 32174, United States
  • Olympian Clinical Research
    Saint Petersburg, Florida 33706, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • DS Research
    Clarksville, Indiana 47129, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • South Bend Clinic
    South Bend, Indiana 46617, United States
  • Options Research Group, LLC
    West Lafayette, Indiana 47906, United States
  • Meridian Clinical Research
    Overland Park, Kansas 66210, United States
  • Qualmedica Research, LLC
    Bowling Green, Kentucky 42101, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Clinical Trials Management, LLC
    Covington, Louisiana 70433, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • DermAssociates, LLC
    Rockville, Maryland 20850, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • Oakland Hills Dermatology, PC
    Auburn Hills, Michigan 48326, United States
  • Michigan Dermatology Institute
    Waterford, Michigan 48328, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • Cleaver Dermatology
    Kirksville, Missouri 63501, United States
  • Vivida Dermatology
    Las Vegas, Nevada 89119, United States
  • Forest Hills Dermatology Group
    Kew Gardens, New York 11415, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • Optima Research
    Boardman, Ohio 44512, United States
  • Remington-Davis, Inc.
    Columbus, Ohio 43215, United States
  • Optimed Research
    Columbus, Ohio 43235, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • Peak Research, LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Palmetto Clinical Trial Services, LLC
    Anderson, South Carolina 29621, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • International Clinical Research - Tennessee, LLC
    Murfreesboro, Tennessee 37130, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Derm Research
    Austin, Texas 78759, United States
  • J&S Studies
    College Station, Texas 77845, United States
  • North Texas Center for Clinical Research
    Frisco, Texas 75034, United States
  • Center for Clinical Studies, Ltd, LLP
    Houston, Texas 77004, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Houston Center for Clinical Research
    Sugar Land, Texas 77479, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Premier Clinical Research, LLC
    Spokane, Washington 99202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2024, 22 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 22 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Oct 7, 2022
StartActual
Sep 15, 2022
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05571943
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
Sep 15, 2022
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Last update
Aug 9, 2024

Study contacts

Uma S Atmuri, MPharm MS
study director · Acrotech Biopharma Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion